Business
Broad-Based Patent Involving Innovative Extracorporeal Treatment Therapy Issued – Premier Biomedical Believes This Could Lead To Cancer Cure
Broad-Based Patent Involving Innovative Extracorporeal Treatment Therapy Issued – Premier Biomedical Believes This Could Lead To Cancer Cure.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n \n Premier Biomedical, Inc. (OTCQB:BIEI) \n a biotech research public company focused on discovering, developing, \n and commercializing medical treatments for a wide range of diseases in \n humans, including innovative therapies for breast cancer as well as \n potential novel therapies for neurofibromatosis, atherosclerosis and \n muscular dystrophy, announced today they have obtained exclusive rights \n to the recently issued U.S. patent, \"Sequential Extracorporeal Treatment \n of Bodily Fluids\" (US Patent #9,216,386, 12/22/15), covering the basic \n technology underpinning Premier's on-going research into new, innovative \n treatments for many of today's most debilitating diseases.\n \n \n Premier Biomedical, Inc. intends to develop its proprietary methodology \n in which the pathologies are eradicated by sequentially dialyzing the \n patient's blood extracorporeally (outside the body). This extracorporeal \n methodology has an enormous potential for dramatically decreasing any \n side effects in the treatment of ill patients. The estimated \n expenditures for cancer treatment in the U.S. in 2010 were approx. \n $124.5 Billion, and projected to rise to $158 - $175 Billion by 20201.\n \n \n William A. Hartman, CEO and President of Premier Biomedical, stated \n that, \"Between this sequential extracorporeal therapy patent just \n issued, and the previously granted patent “Utilization of Stents for the \n Treatment of Blood Borne Carcinomas” (US Patent #8,758,287: 6/24/14), I \n believe that we have a clear roadmap for potentially curing cancer, \n possibly at any stage, and even after extensive metastasis. These \n patents support our on-going experimentation and plans to present our \n stunning results to the American Association for Cancer Research (AACR) \n in April.” Contact Premier via email at [email protected] \n or by phone at (PBI) MED-7033 / (724) 633-7033.\n \n \n About Premier Biomedical, Inc.\n \n \n Premier Biomedical, Inc. is a research-based company that intends to \n discover and develop medical treatments for a wide range of diseases in \n humans, initially targeting the treatment of cancer. The Company's \n common stock trades on the Over-The-Counter Bulletin Board under the \n ticker symbol \"BIEI.\" http://www.premierbiomedicalinc.com/\n \n \n Safe Harbor Notice\n \n \n Stateme...